CN100389819C - Chinese-medicine for treating cataracta ophthalmopathy - Google Patents
Chinese-medicine for treating cataracta ophthalmopathy Download PDFInfo
- Publication number
- CN100389819C CN100389819C CNB2006100429474A CN200610042947A CN100389819C CN 100389819 C CN100389819 C CN 100389819C CN B2006100429474 A CNB2006100429474 A CN B2006100429474A CN 200610042947 A CN200610042947 A CN 200610042947A CN 100389819 C CN100389819 C CN 100389819C
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- semen
- rhizoma
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating cataract is prepared from 18 Chinese-medicinal materials including coptis root, scutellaria root, Chuan-xiong rhizome, Chinese angelica root, etc.
Description
Technical field:
The invention belongs to medical technical field, be specifically related to a kind of Chinese medicine for the treatment of cataracta ophthalmopathy.
Background technology:
The pathogenic factor of cataracta ophthalmopathy mainly is that internal organs meridians physiology pathological changes can not be coordinated, cause vital organs of the human body vital essence can not on fail in order, thereby cause eyes generation pathological changes.Cataracta ophthalmopathy mainly comprises glaucoma, cataract, view pathological changes, retinal hemorrhage etc.At present, treat the medicine of the difficult oculopathy of such cataract, weak effect aspect the practical application curative effect, main cause is unclear to the pathology of cataracta ophthalmopathy, the medicine of research can not be at all cataracta ophthalmopathies, thereby existing medicine exists slow, the weak effect of taking effect, treatment not thoroughly and can produce the problem of sequela in various degree.
Summary of the invention:
The present invention will provide a kind of Chinese medicine for the treatment of cataracta ophthalmopathy, and, weak effect slow with taking effect of overcoming that prior art exists, treatment are not thoroughly and can produce the problem of sequela in various degree.
For overcoming the problem that prior art exists, the technical solution used in the present invention is: a kind of Chinese medicine for the treatment of cataracta ophthalmopathy, it is characterized in that it is made up of the composition of following weight proportion,
8 parts～12 parts of Rhizoma Coptidis, 2 parts～4 parts of Radix Saposhnikoviaes, 2 parts～4 parts of Herba Asaris, 4 parts～8 parts of Radix Scutellariaes, 4 parts～8 parts of Rhizoma Chuanxiongs, 4 parts～8 parts of Herba Lophatheris, 4 parts～8 parts of Semen Cassiae, 4 parts～8 parts of the Radixs Angelicae Dahuricae, 2 parts～4 parts of shepherd's purses, 2 parts～4 parts of Mirabilitums, 4 parts～8 parts in nitron stone, 2 parts～4 parts in Gypsum Fibrosum, 4 parts～8 parts of Rhizoma Alismatis, 4 parts～8 parts of Semen Plantaginiss, 4 parts～8 parts of the Fructus Kochiae, 4 parts～8 parts of Herba Dianthis, 4 parts～8 parts of Radix Paeoniaes, 4 parts～8 parts of Radix Angelicae Sinensis, 4 parts～8 parts in Semen Persicae, 2 parts～4 parts of Stigma Croci, 4 parts～8 parts of Concha Haliotidis, 4 parts～8 parts of Cornu Saigae Tataricae, 2 parts～4 parts of Radix Adenophorae (Radix Glehniae), 4 parts～8 parts of Semen Platycladis, 4 parts～8 parts of Nux Prinsepiae, 2 parts～4 parts of Cortex Cinnamomis, 4 parts～8 parts of Radix Panacis Quinquefoliis, 4 parts～8 parts of Fructus Corni, 2 parts～4 parts of Radix Aconitis, 2 parts～4 parts of Rhizoma Zingiberis Preparatums, 2 parts～4 parts of Flos Caryophyllis, 1 part～3 parts in Borneolum Syntheticum, 2 parts～4 parts of Margaritas, 2 parts～4 parts in Radix Glycyrrhizae, 4 parts～8 parts of Cortex Fraxinis, 2 parts～4 parts of Flos Magnoliae.
The preferred version of the Chinese medicine of above-mentioned treatment cataracta ophthalmopathy is to be made up of the composition of following weight proportion: 10 parts～12 parts of Rhizoma Coptidis, 3 parts～4 parts of Radix Saposhnikoviaes, 3 parts～4 parts of Herba Asaris, 6 parts～8 parts of Radix Scutellariaes, 6 parts～8 parts of Rhizoma Chuanxiongs, 6 parts～8 parts of Herba Lophatheris, 6 parts～8 parts of Semen Cassiae, 6 parts～8 parts of the Radixs Angelicae Dahuricae, 3 parts～4 parts of shepherd's purses, 3 parts～4 parts of Mirabilitums, 7 parts～8 parts in nitron stone, 3 parts～4 parts in Gypsum Fibrosum, 6 parts～8 parts of Rhizoma Alismatis, 4 parts～5 parts of Semen Plantaginiss, 6 parts～8 parts of the Fructus Kochiae, 4 parts～6 parts of Herba Dianthis, 4 parts～6 parts of Radix Paeoniaes, 4 parts～6 parts of Radix Angelicae Sinensis; 4 parts～6 parts in Semen Persicae, 2 parts～3 parts of Stigma Croci, 4 parts～5 parts of Concha Haliotidis, 4 parts～6 parts of Cornu Saigae Tataricae, 2 parts～3 parts of Radix Adenophorae (Radix Glehniae), 6 parts～8 parts of Semen Platycladis, 4 parts～6 parts of Nux Prinsepiae, 2 parts～3 parts of Cortex Cinnamomis, 6 parts～8 parts of Radix Panacis Quinquefoliis, 4 parts～6 parts of Fructus Corni, 2 parts～3 parts of Radix Aconitis, 2 parts～3 parts of Rhizoma Zingiberis Preparatums, 2 parts～3 parts of Flos Caryophyllis, 2 parts～3 parts in Borneolum Syntheticum, 2 parts～3 parts of Margaritas, 2 parts～3 parts in Radix Glycyrrhizae, 4 parts～6 parts of Cortex Fraxinis, 2 parts～3 parts of Flos Magnoliae.
Fang Yi of the present invention is interpreted as: especially the difficult oculopathy of cataract is when clinical treatment for cataracta ophthalmopathy, and often because of heresy has the folder of holding concurrently, body constitution is different, and sick position and symptom difference can not only be used a kind of method of treatment, and need a few method compatibilities to use, to suit the needs of the state of an illness.The treatment characteristics of the difficult oculopathy of the outstanding cataract of we, adopt a method among eight therapeutic methods possess the theory that hundred methods possess among the eight therapeutic methods.Rhizoma Coptidis, Radix Saposhnikoviae, Herba Asari, Radix Scutellariae, Rhizoma Chuanxiong, Herba Lophatheri, Semen Cassiae, the Radix Angelicae Dahuricae, shepherd's purse, Mirabilitum, nitron stone, Gypsum Fibrosum are monarch drug altogether among the present invention, but heat-clearing and toxic substances removing, the hot wet dispelling wind of dispersing, remove the burning hot harmful substance in the body of discharging, cleanse real banking fire poison, asthenic fire falls in YIN nourishing, and is analgesic relieving convulsion, plays function of gallbladder promoting, diuresis, blood pressure lowering, antiinflammatory and analgesic effect.Rhizoma Alismatis, Semen Plantaginis, the Fructus Kochiae, Herba Dianthi, Radix Paeoniae, Radix Angelicae Sinensis are ministerial drug altogether, but the turbid diuretic of damp eliminatingization is changed the disease silt of dispelling, blood fat reducing, diuresis, cholesterol reducing, hard masses softening and resolving, the disease of dispelling.Semen Persicae, Stigma Croci, Concha Haliotidis, Cornu Saigae Tataricae, Radix Adenophorae (Radix Glehniae), Semen Platycladi, Nux Prinsepiae, Cortex Cinnamomi, Radix Panacis Quinquefolii, Fructus Corni, Radix Aconiti, Rhizoma Zingiberis Preparatum, Flos Caryophylli, Borneolum Syntheticum, Margarita, Radix Glycyrrhizae, Cortex Fraxini and Flos Magnoliae make for assistant altogether, play blood-activating and qi-promoting, promoting blood circulation and removing blood stasis, separate stagnation of liver-QI, smooth gas and conditioning viscera, suppressing the hyperactive liver to relieve the wind syndrome, Yin Yang balancing, benefiting qi and nourishing blood, liver and kidney tonifying, with with make eye bright, anticoagulant haemolysis strengthens the molten speed of blood, liver heat removing and eyesight improving, removing pathogenic heat from blood and toxic substance from the body, heart tonifying, the effect of coronary artery dilator, cerebrovascular, optical fundus blood vessel.
Multiple medicine general character among the present invention merges, and can play antiinflammatory, and is antipruritic, pain relieving, and the mediation the exterior and the interior, heat-clearing and toxic substances removing, toxin expelling, activating blood circulation to dissipate blood stasis, QI and blood is two transfers, and can strengthen hepatic and renal function, and lesions position is recovered rapidly, thereby reaches the purpose for the treatment of oculopathy and improving vision.It is advantageous that:
1. with strong points; The cataracta ophthalmopathy main cause is that internal organs meridians physiology pathological changes can not be coordinated, cause vital organs of the human body vital essence can not on fail in order, thereby cause eyes generation pathological changes, according to pathological changes symptom difference, we are from clearing away heat and purging, nourishing YIN to lower pathogenic fire, make that outer six climate exopathogens heat-transformation is lit a fire, visceral dysfunction, in light a fire heresy or five will heat-transformation etc. intimately disease dissolved, flourishing, excess-heat pents up, and drops to discharge to alleviate top focus pressure, with hemostasis and pain-relieving, lightly ooze damp eliminating and strengthen the metabolism of water liquid, help muddy edema and eliminate.
2. can quicken transudate discharges, strengthening self absorbs: to the exudative inflammation internal ophthalmopathy, it is very important reaching the long external eyes disease of medical history, and water overflows and is disease, the ridging replenishing essence, we's treating both the principal and secondary aspects of a disease, the silt of dispelling of reducing phlegm, phlegm-eliminiating and qi-regulating, the reducing phlegm, expelling pathologic wind collateral dredging, make eye bright, the nourishing yin and promoting blood circulation diuretic is removed the absorption hematocele.
3. the activating blood circulation to dissipate blood stasis effect is obvious; Blood circulation depending on qi flow, qi stagnation blood stasis is with promoting blood circulation, promote that blood is capable, dissipate and be retarded by silt blood-activating and qi-promoting, resolving blood stasis and dredging collateral, regulating functional activities of qi dissipates and is retarded by silt, nourishing the liver and blood, the balance internal organs, suppressing the hyperactive liver is grown sun, both tranquillizing the mind by relieving convulsion made eye bright, and the removing heat from the liver nebula removing hinders again, visual acuity is obtained from the sufficient blood supply of the eyes, benefiting QI and nourishing blood, the kidney invigorating nourishing the liver, refreshing light (vision) depend on the very smart nourishing of the true blood of vital qi, so QI and blood is most important to eyes.The present invention destroys the pathogen activity from the control cause of disease, destroys pathogen and sets out, and reaches the recovery spheroid and organizes function, repairs the effect that spheroid is organized function.
Advantage has embodied the outstanding unique effect of the present invention in the treatment cataracta ophthalmopathy in sum.Compared with prior art, advantage of the present invention is:
1, take effect rapidly: show in the clinical treatment that glaucoma can take effect general 1～3 course of treatment, can fully recover 3～5 courses of treatment; Cataract just can take effect general 1～2 course of treatment in mid-term, and can fully recover 3～6 courses of treatment; The view pathological changes can take effect general 1～2 course of treatment, and can fully recover 2～3 courses of treatment; Retinal hemorrhage is in time treated when disease is sent out, and can take effect general 1～2 course of treatment, and can fully recover 2～5 courses of treatment; The old retinal hemorrhage, can take effect general 1～3 course of treatment, and can fully recover 3～6 courses of treatment.
2, good effect: determined curative effect of the present invention, obvious to the therapeutic effect of all kinds cataracta ophthalmopathy, through the treatment demonstration of 100 many cases, obvious effective rate of the present invention reaches 96%, and effective percentage can reach 90%, and cure rate can reach 85%.
3, safe and reliable: the present invention not only can reach ideal therapeutic effect when treatment finishes, and can not produce sequela.
4, have no side effect: show through toxicity test, do not see obvious toxic and side effects, take safe and reliable for a long time.
5, therapeutic domain is extensive: the present invention not only can treat the cataracta ophthalmopathy of general type, more the treatment to difficult type cataracta ophthalmopathy has unique curative effect, for example severe view pathological changes oculopathy is treated, can take effect general 2～3 courses of treatment, and can fully recover 3～5 courses of treatment.
The specific embodiment:
To elaborate to the present invention with specific embodiment below.
Embodiment 1:
8 parts of Rhizoma Coptidis, 2 parts of Radix Saposhnikoviaes, 2 parts of Herba Asaris, 4 parts of Radix Scutellariaes, 4 parts of Rhizoma Chuanxiongs, 4 parts of Herba Lophatheris, 4 parts of Semen Cassiae, 4 parts of the Radixs Angelicae Dahuricae, 2 parts of shepherd's purses, 2 parts of Mirabilitums, 4 parts in nitron stone, 2 parts in Gypsum Fibrosum, 8 parts of Rhizoma Alismatis, 8 parts of Semen Plantaginiss, 8 parts of the Fructus Kochiae, 6 parts of Herba Dianthis, 6 parts of Radix Paeoniaes, 6 parts of Radix Angelicae Sinensis, 8 parts in Semen Persicae, 4 parts of Stigma Croci, 8 parts of Concha Haliotidis, 8 parts of Cornu Saigae Tataricae, 4 parts of Radix Adenophorae (Radix Glehniae), 8 parts of Semen Platycladis, 8 parts of Nux Prinsepiae, 2 parts of Cortex Cinnamomis, 4 parts of Radix Panacis Quinquefoliis, 4 parts of Fructus Corni, 2 parts of Radix Aconitis, 2 parts of Rhizoma Zingiberis Preparatums, 2 parts of Flos Caryophyllis, 1 part in Borneolum Syntheticum, 2 parts of Margaritas, 2 parts in Radix Glycyrrhizae, 4 parts of 4 parts of Cortex Fraxinis and Flos Magnoliae.
Embodiment 2:
10 parts of Rhizoma Coptidis, 4 parts of Radix Saposhnikoviaes, 2 parts of Herba Asaris, 8 parts of Radix Scutellariaes, 4 parts of Rhizoma Chuanxiongs, 8 parts of Herba Lophatheris, 4 parts of Semen Cassiae, 8 parts of the Radixs Angelicae Dahuricae, 2 parts of shepherd's purses, 4 parts of Mirabilitums, 4 parts in nitron stone, 4 parts in Gypsum Fibrosum, 4 parts of Rhizoma Alismatis, 8 parts of Semen Plantaginiss, 4 parts of the Fructus Kochiae, 8 parts of Herba Dianthis, 4 parts of Radix Paeoniaes, 8 parts of Radix Angelicae Sinensis, 8 parts in Semen Persicae, 2 parts of Stigma Croci, 8 parts of Concha Haliotidis, 4 parts of Cornu Saigae Tataricae, 4 parts of Radix Adenophorae (Radix Glehniae), 8 parts of Semen Platycladis, 4 parts of Nux Prinsepiae, 4 parts of Cortex Cinnamomis, 4 parts of Radix Panacis Quinquefoliis, 8 parts of Fructus Corni, 2 parts of Radix Aconitis, 4 parts of Rhizoma Zingiberis Preparatums, 2 parts of Flos Caryophyllis, 3 parts in Borneolum Syntheticum, 4 parts of Margaritas, 2 parts in Radix Glycyrrhizae, 3 parts of 8 parts of Cortex Fraxinis and Flos Magnoliae.
Embodiment 3:
12 parts of Rhizoma Coptidis, 4 parts of Radix Saposhnikoviaes, 4 parts of Herba Asaris, 8 parts of Radix Scutellariaes, 8 parts of Rhizoma Chuanxiongs, 8 parts of Herba Lophatheris, 7 parts of Semen Cassiae, 6 parts of the Radixs Angelicae Dahuricae, 4 parts of shepherd's purses, 4 parts of Mirabilitums, 8 parts in nitron stone, 4 parts in Gypsum Fibrosum, 6 parts of Rhizoma Alismatis, 4 parts of Semen Plantaginiss, 6 parts of the Fructus Kochiae, 4 parts of Herba Dianthis, 6 parts of Radix Paeoniaes, 4 parts of Radix Angelicae Sinensis, 4 parts in Semen Persicae, 2 parts of Stigma Croci, 4 parts of Concha Haliotidis, 4 parts of Cornu Saigae Tataricae, 2 parts of Radix Adenophorae (Radix Glehniae), 8 parts of Semen Platycladis, 4 parts of Nux Prinsepiae, 3 parts of Cortex Cinnamomis, 6 parts of Radix Panacis Quinquefoliis, 4 parts of Fructus Corni, 3 parts of Radix Aconitis, 3 parts of Rhizoma Zingiberis Preparatums, 2 parts of Flos Caryophyllis, 2 parts in Borneolum Syntheticum, 2 parts of Margaritas, 2 parts in Radix Glycyrrhizae, 2 parts of 4 parts of Cortex Fraxinis and Flos Magnoliae.
The foregoing description 3 is preferable.
Preparation technology of the present invention is conventional Chinese medicine preparation technology, and the processing of various components is all carried out routinely.The present invention can be prepared as various form of Chinese drug.
Of the present inventionly take that to be prepared into granule with embodiment 3 be example, be 20 days a course of treatment, divides every day and take for three times, and each dose is 6～9 grams.
Claims (2)
1. Chinese medicine for the treatment of cataracta ophthalmopathy, it is made up of the composition of following weight proportion: 8 parts～12 parts of Rhizoma Coptidis, 2 parts～4 parts of Radix Saposhnikoviaes, 2 parts～4 parts of Herba Asaris, 4 parts～8 parts of Radix Scutellariaes, 4 parts～8 parts of Rhizoma Chuanxiongs, 4 parts～8 parts of Herba Lophatheris, 4 parts～8 parts of Semen Cassiae, 4 parts～8 parts of the Radixs Angelicae Dahuricae, 2 parts～4 parts of shepherd's purses, 2 parts～4 parts of Mirabilitums, 4 parts～8 parts in nitron stone, 2 parts～4 parts in Gypsum Fibrosum, 4 parts～8 parts of Rhizoma Alismatis, 4 parts～8 parts of Semen Plantaginiss, 4 parts～8 parts of the Fructus Kochiae, 4 parts～8 parts of Herba Dianthis, 4 parts～8 parts of Radix Paeoniaes, 4 parts～8 parts of Radix Angelicae Sinensis, 4 parts～8 parts in Semen Persicae, 2 parts～4 parts of Stigma Croci, 4 parts～8 parts of Concha Haliotidis, 4 parts～8 parts of Cornu Saigae Tataricae, 2 parts～4 parts of Radix Adenophorae (Radix Glehniae), 4 parts～8 parts of Semen Platycladis, 4 parts～8 parts of Nux Prinsepiae, 2 parts～4 parts of Cortex Cinnamomis, 4 parts～8 parts of Radix Panacis Quinquefoliis, 4 parts～8 parts of Fructus Corni, 2 parts～4 parts of Radix Aconitis, 2 parts～4 parts of Rhizoma Zingiberis Preparatums, 2 parts～4 parts of Flos Caryophyllis, 1 part～3 parts in Borneolum Syntheticum, 2 parts～4 parts of Margaritas, 2 parts～4 parts in Radix Glycyrrhizae, 4 parts～8 parts of Cortex Fraxinis, 2 parts～4 parts of Flos Magnoliae.
2. a kind of Chinese medicine for the treatment of cataracta ophthalmopathy as claimed in claim 1, it is characterized in that: the composition by following weight proportion is formed, 10 parts～12 parts of Rhizoma Coptidis, 3 parts～4 parts of Radix Saposhnikoviaes, 3 parts～4 parts of Herba Asaris, 6 parts～8 parts of Radix Scutellariaes, 6 parts～8 parts of Rhizoma Chuanxiongs, 6 parts～8 parts of Herba Lophatheris, 6 parts～8 parts of Semen Cassiae, 6 parts～8 parts of the Radixs Angelicae Dahuricae, 3 parts～4 parts of shepherd's purses, 3 parts～4 parts of Mirabilitums, 7 parts～8 parts in nitron stone, 3 parts～4 parts in Gypsum Fibrosum, 6 parts～8 parts of Rhizoma Alismatis, 4 parts～5 parts of Semen Plantaginiss, 6 parts～8 parts of the Fructus Kochiae, 4 parts～6 parts of Herba Dianthis, 4 parts～6 parts of Radix Paeoniaes, 4 parts～6 parts of Radix Angelicae Sinensis, 4 parts～6 parts in Semen Persicae, 2 parts～3 parts of Stigma Croci, 4 parts～5 parts of Concha Haliotidis, 4 parts～6 parts of Cornu Saigae Tataricae, 2 parts～3 parts of Radix Adenophorae (Radix Glehniae), 6 parts～8 parts of Semen Platycladis, 4 parts～6 parts of Nux Prinsepiae, 2 parts～3 parts of Cortex Cinnamomis, 6 parts～8 parts of Radix Panacis Quinquefoliis, 4 parts～6 parts of Fructus Corni, 2 parts～3 parts of Radix Aconitis, 2 parts～3 parts of Rhizoma Zingiberis Preparatums, 2 parts～3 parts of Flos Caryophyllis, 2 parts～3 parts in Borneolum Syntheticum, 2 parts～3 parts of Margaritas, 2 parts～3 parts in Radix Glycyrrhizae, 4 parts～6 parts of Cortex Fraxinis, 2 parts～3 parts of Flos Magnoliae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100429474A CN100389819C (en) | 2006-06-09 | 2006-06-09 | Chinese-medicine for treating cataracta ophthalmopathy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100429474A CN100389819C (en) | 2006-06-09 | 2006-06-09 | Chinese-medicine for treating cataracta ophthalmopathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1895648A CN1895648A (en) | 2007-01-17 |
| CN100389819C true CN100389819C (en) | 2008-05-28 |
Family
ID=37608391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100429474A Expired - Fee Related CN100389819C (en) | 2006-06-09 | 2006-06-09 | Chinese-medicine for treating cataracta ophthalmopathy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100389819C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103340949B (en) * | 2013-07-10 | 2014-07-02 | 穆宗玲 | Eye drops for removing nebula and cataract |
| CN105935437A (en) * | 2016-03-29 | 2016-09-14 | 周剑峰 | Eyesight-improving traditional Chinese medicine wine |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1097615A (en) * | 1993-07-22 | 1995-01-25 | 常毅坚 | Nephelium clearing eye drops |
| CN1149481A (en) * | 1996-04-16 | 1997-05-14 | 郭良才 | Capsule for enhancing eyesight |
| CN1213564A (en) * | 1998-09-30 | 1999-04-14 | 孟庆然 | Chinese medicinal pills for treating catarct and its prodn. method |
-
2006
- 2006-06-09 CN CNB2006100429474A patent/CN100389819C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1097615A (en) * | 1993-07-22 | 1995-01-25 | 常毅坚 | Nephelium clearing eye drops |
| CN1149481A (en) * | 1996-04-16 | 1997-05-14 | 郭良才 | Capsule for enhancing eyesight |
| CN1213564A (en) * | 1998-09-30 | 1999-04-14 | 孟庆然 | Chinese medicinal pills for treating catarct and its prodn. method |
Non-Patent Citations (4)
| Title |
|---|
| 中医眼科外用药的应用. 肖家翔.中国中医药现代远程教育，第2卷第12期. 2004 |
| 中医眼科外用药的应用. 肖家翔.中国中医药现代远程教育，第2卷第12期. 2004 * |
| 千金翼方. 孙思邈，10,45，辽宁科学技术出版社. 1997 |
| 千金翼方. 孙思邈，10,45，辽宁科学技术出版社. 1997 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1895648A (en) | 2007-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101121012B (en) | Traditional Chinese medicine for treating external oculopathy eye disease | |
| CN100389819C (en) | Chinese-medicine for treating cataracta ophthalmopathy | |
| CN102631632B (en) | Preparation method of traditional Chinese medicine lotion for treating blood stasis type pustule on sole | |
| CN102579991B (en) | Traditional Chinese medicine composition for treating herpes simplex viral keratitis | |
| CN102178902B (en) | Method for preparing Chinese medicine for treating liver stagnation type acute pancreatitis | |
| CN1857540A (en) | Oral medicine liquid for treating rheumatic diseases and its preparing method | |
| CN102743696B (en) | Preparation method of traditional Chinese medicine lotion for treating blood stasis type cellulitis | |
| CN102198193A (en) | Method for preparing Chinese medicine for treating wind- and fire-rooted glaucoma | |
| CN101181433B (en) | Chinese medicine medicament for curing pterygium | |
| CN101249212B (en) | Externally used drug for curing epidemic parotitis | |
| CN106362089A (en) | External medicine for treating eye diseases | |
| CN102872416B (en) | Traditional Chinese medicine sitting lotion for treating chronic prostatitis | |
| CN102579623B (en) | Preparation method of Chinese lotion for treating traumatic type ecthyma | |
| CN100384465C (en) | Chinese medicinal preparation for treating cancer and tumor and preparation method thereof | |
| CN105079648A (en) | Medicine for preventing and treating myopia | |
| CN102416114A (en) | Chinese medicinal composition for treating condyloma acuminatum | |
| CN102743623A (en) | Preparation method of Chinese medicine irrigation solution for treating frequent micturition and urgent micturition type trichomonas vaginitis | |
| CN102327497B (en) | Method for preparing traditional Chinese medicine lotion for treating eclamptic bedsore | |
| CN102671112B (en) | Preparation method of traditional Chinese medicine for treating blood stasis ecthyma | |
| CN102743698A (en) | Preparation method of traditional Chinese medicine lotion for treating pain type cellulitis | |
| CN106138566A (en) | One treats physical fatigue Chinese medicinal liquor and preparation method thereof | |
| CN105770322A (en) | Preparation method of medical liquor for treating blood-stasis type lumbago | |
| CN105233070A (en) | Traditional Chinese medicine composition for treating dysmenorrhea | |
| CN102614455B (en) | Preparation method of traditional Chinese medicine lotion for treating pain-type ecthyma | |
| CN201814826U (en) | Dynamic wave vision correction instrument |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080528 Termination date: 20160609 |